康莱特对局部晚期乳腺癌新辅助化疗耐受性的影响

[目的]探讨康莱特对局部晚期乳腺癌新辅助化疗耐受性的影响。[方法]60例局部晚期乳腺癌患者分为康莱特组和对照组．两组均行CEF方案化疗，康莱特组同时给予康莱特200ml／d。观察两组骨髓抑制，CD3＋、CD4＋、CD8＋、CD4／CD8及Kamofsky评分变化。[结果]康莱特组和对照组≥3级骨髓抑制发生率分别为13.3％（4／30）、50．0％（15／30），差异有显著性（P〈0．05）。康莱特组CD3＋、CD4＋、CD4／CD8均显著性高于对照组（P=0．032，P=0．038，P=0．040）。康莱特组生活质量为稳定、减退的患者分别为22、5例，对照组分别为18、10例，两组稳定、减退率均有显著性差异（P=0．044，P=0．030）。[结论]康莱特联合新辅助化疗可以减轻局部晚期乳腺癌患者骨髓抑制．提高免疫功能和化疗耐受性。

The Effect to KLT on Neoadjuvant Chemotherapy Tolerance in Patients with Locally Advanced Breast Cancer

[Purposel To investigate the effect to KLT on neoadjuvant chemotherapy tolerance in pa- tients with locally advanced breast cancer. [ Method ] Sixty patients with locally advanced breast cancer （LABC） were divided into KLT group and control group. All patients received neoadjuvant chemotherapy based on CEF regimen, and patients in KLT group given KLT 200ml/d. The mylosuppresion,CD3＋ ,CD4＋ ,CD8＋ ,CD4 / CD8 and Kamofsky were observed. [Result] The degree ≥3 myelosuppression in KLT group and control group was 13.3% （4/30）,50.0% （15/30） respectively, with significant differences （P〈0.05）.The CD3＋,CD4＋ and CD4/CD8 in KLT group were higher than those in control group （P=0.032,P=0.038,P=0.040）.There were significant differences in quality of life of stability and decreased between KLT group and control group （22 cases vsl8 cases,P=0.044; 5 cases vsl0 cases,P=0.030）. [Conclusion] KLT combined with neoadjuvant chemotherapy in patients with LABC can reduce mylosuppresion,improve immunity and chemotherapy tolerance.